Abstract
From 1956 to 1968, 60 children were diagnosed as having acute myelogenousleukemia or one of its morphologic subgroups. All patients received chemotherapy, and until early 1968, this consisted of conventional agents used alone or in combination. After mid-1968, a therapeutic departure was made, and 7 patients were treated with a combination of cyclophosphamide and cytosine arabinoside intravenously. The median duration of survival for all patients was 1.5 months; there was no significant improvement from 1956 to early 1968. However, after mid-1968, the median duration was 9.5 months. This experience and that of others suggests that improved response and prolonged survival can be attributed to intensified use of the newer chemotherapeutic agents and by recent developments in supportive care.
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
